TOKYO--(BUSINESS WIRE)--Orasi Medical (R) (“Orasi”), www.orasimedical.com , a clinical-stage pharmaceutical services company that develops technology to measure brain function for tracking Alzheimer’s disease and other brain related disorders, today announced the opening of its new Tokyo office on September 14, 2009. The new office will allow Orasi Medical (R) to aid Japanese pharmaceutical companies in developing medicines for CNS diseases, such as Alzheimer’s disease, Multiple Sclerosis, Schizophrenia, Parkinson’s disease, and Migraine. After receiving $6 million in funding to date, the Red Herring 2009 Award, reviews by the Economist1 and Star Tribune2, and offering the only non-invasive 10 minute test that tracks Alzheimer’s disease progression for use in clinical trials, which is backed by peer-reviewed scientific publications3,4,5,6, Orasi Medical (R) is on a roll to tackle one of the biggest medical problems to face Japan and the rest of the world: Alzheimer’s disease.
